Please Wait
Applying Filters...
Menu
Xls

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/head-to-head-superiority-over-dulaglutide-innovents-phase-3-clinical-trial-dreams-2-of-mazdutide-in-chinese-patients-with-type-2-diabetes-were-orally-presented-at-easd-2024-302244860.html

PR NEWSWIRE
11 Sep 2024

https://www.prnewswire.com/news-releases/innovent-annouces-multiple-clinical-study-results-of-mazdutide-to-be-presented-at-the-easd-2024-302235586.html

PR NEWSWIRE
01 Sep 2024

https://www.biospace.com/drug-development/innovents-lilly-partnered-type-2-diabetes-drug-aces-phase-iii-in-china-inches-closer-to-approval

BIOSPACE
23 Jul 2024

https://www.prnewswire.com/news-releases/innovent-provides-interpretation-and-updates-on-clinical-data-from-mazdutide-glory-1-study-and-general-biomedicine-pipeline-302184351.html

PR NEWSWIRE
27 Jun 2024

https://www.prnewswire.com/news-releases/innovent-to-present-multiple-clinical-study-results-of-mazdutide-at-the-adas-84th-scientific-sessions-302169495.html

PR NEWSWIRE
12 Jun 2024
Lilly's next-gen obesity drug brings Innovent ph. 3 diabetes win
Lilly's next-gen obesity drug brings Innovent ph. 3 diabetes win

09 May 2024

// James Waldron FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/lillys-next-gen-obesity-drug-brings-innovent-phase-3-win-diabetes

James Waldron FIERCE BIOTECH
09 May 2024